Literature DB >> 9222290

Dominant-negative mutations of the Wilms' tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia.

M Carapeti1, J M Goldman, N C Cross.   

Abstract

To determine if mutations of the Wilms' tumor predisposing gene (WT1) are associated with haematological malignancies, we have investigated 65 cases of acute leukaemia, including 39 patients in blast crisis of chronic myeloid leukaemia (CML), by amplification of WT1 exons 7, 8 and 9 followed by single-strand conformation polymorphism analysis. WT1 transcripts were detected by RT-PCR in all samples. An exon 7 silent polymorphism (A-->G; Arg 313) was identified in 17 individuals, 5 of whom were homozygous, but no other lesions were found. In 1 sample from a patient with acute lymphoblastic leukaemia a smaller size transcript missing exon 9 was detected; a similar abnormality has been described previously in a patient with Wilms' tumour and the resultant protein shown to act in a dominant-negative manner. No mutations of the exon 9 donor or acceptor splice sites were found in this patient and the basis of the abnormal transcript remains obscure. We conclude that dominant-negative mutations of the zinc finger region of the WT1 gene are uncommon in CML blast crisis. Abnormalities of this gene may, however, contribute to a small proportion of cases of de novo acute leukaemia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9222290     DOI: 10.1111/j.1600-0609.1997.tb01681.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  5 in total

Review 1.  The possible role and application of WT1 in human leukemia.

Authors:  Z Chen
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

Review 2.  Wilms' tumor gene WT1: its oncogenic function and clinical application.

Authors:  H Sugiyama
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

3.  WT1 mutations in T-ALL.

Authors:  Valeria Tosello; Marc R Mansour; Kelly Barnes; Maddalena Paganin; Maria Luisa Sulis; Sarah Jenkinson; Christopher G Allen; Rosemary E Gale; David C Linch; Teresa Palomero; Pedro Real; Vundavalli Murty; Xiaopan Yao; Susan M Richards; Anthony Goldstone; Jacob Rowe; Giuseppe Basso; Peter H Wiernik; Elisabeth Paietta; Rob Pieters; Martin Horstmann; Jules P P Meijerink; Adolfo A Ferrando
Journal:  Blood       Date:  2009-06-03       Impact factor: 22.113

4.  Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels.

Authors:  Amy Guillaumet-Adkins; Julia Richter; Maria D Odero; Juan Sandoval; Xabi Agirre; Albert Catala; Manel Esteller; Felipe Prósper; María José Calasanz; Ismael Buño; Mi Kwon; Franck Court; Reiner Siebert; David Monk
Journal:  J Hematol Oncol       Date:  2014-01-09       Impact factor: 17.388

5.  Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells.

Authors:  M Carapeti; R C Aguiar; H Sill; J M Goldman; N C Cross
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.